Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05445778 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer(GLORIOSA) | active not recruiting | Phase 3 | 520 | AbbVieINDUSTRY |
| 22 |
| Jun 2, 2026 |
| clinicaltrials |
| NCT07120945 | Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)(Embrace Gyn) | active not recruiting | N/A | 70 | Medtronic - MITGINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07341100 | Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC | active not recruiting | Phase 2 | 20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 692 | National Cancer Institute (NCI)NIH | 3 | May 29, 2026 | clinicaltrials |
| NCT05200559 | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 25 | Alexander B Olawaiye, MDOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT04009148 | Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome | active not recruiting | — | 118 | NYU Langone HealthOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT05691504 | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT04502602 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer(iNNOVATE) | active not recruiting | Phase 1 | 18 | Virginia Commonwealth UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04553133 | PF-07104091 as a Single Agent and in Combination Therapy | active not recruiting | Phase 2 | 157 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT05271318 | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.(PROTA) | active not recruiting | Phase 1 / Phase 2 | 29 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT03393884 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)(OVATION 2) | active not recruiting | Phase 1 / Phase 2 | 130 | ImunonINDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT07555639 | An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity(GERSOM) | active not recruiting | N/A | 4,000 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06065358 | Ovarian Tumor Organotypic Slices Cultures for functionAl Drug Testing and Therapy Response Prediction(TOSCA) | active not recruiting | N/A | 48 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT01907789 | Prophylactic Salpingectomy With Delayed Oophorectomy | active not recruiting | N/A | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04125914 | Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families | active not recruiting | N/A | 384 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02043158 | Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer | active not recruiting | — | 240 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02659241 | Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Early Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03965481 | PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer | active not recruiting | N/A | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04678414 | Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer | active not recruiting | — | 1,410 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03772028 | Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)(OVHIPEC-2) | active not recruiting | Phase 3 | 538 | The Netherlands Cancer InstituteOTHER | 7 | Apr 8, 2026 | clinicaltrials |
| NCT00579514 | Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | active not recruiting | N/A | 21,081 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03017131 | Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04938583 | Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 54 | CanariaBio Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03428802 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | active not recruiting | Phase 2 | 21 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05335993 | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | active not recruiting | Phase 2 | 10 | CanariaBio Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06342986 | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | active not recruiting | Phase 1 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02873962 | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | active not recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04498117 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery(FLORA-5) | active not recruiting | Phase 3 | 615 | CanariaBio Inc.INDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT05605535 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 2 | 88 | CanariaBio Inc.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT01977274 | Predictive Clinical and Biological Parameters in Gynecological Cancer(GC-BIO) | active not recruiting | N/A | 300 | Institut Paoli-CalmettesOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT05514028 | Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin(OVAmiARN) | active not recruiting | — | 746 | ZIWIGINDUSTRY | 3 | Mar 30, 2026 | clinicaltrials |
| NCT00587886 | Estrogen, Diet, Genetics and Endometrial Cancer | active not recruiting | — | 1,315 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04095364 | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 450 | NRG OncologyOTHER | 6 | Mar 24, 2026 | clinicaltrials |
| NCT03519230 | Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer | active not recruiting | Phase 3 | 224 | BeiGeneINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03842982 | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)(CHIPPI) | active not recruiting | Phase 3 | 362 | Centre Oscar LambretOTHER | 2 | Mar 16, 2026 | clinicaltrials |
| NCT03875820 | Phase I Trial of Defactinib and VS-6766.(FRAME) | active not recruiting | Phase 1 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05116189 | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). | active not recruiting | Phase 3 | 643 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Mar 9, 2026 | clinicaltrials |
| NCT07109414 | Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) | active not recruiting | Phase 2 / Phase 3 | 380 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT01970722 | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | active not recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06028932 | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | active not recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04884360 | D9319C00001- 1L OC Mono Global RCT(MONO-OLA1) | active not recruiting | Phase 3 | 366 | AstraZenecaINDUSTRY | 10 | Mar 2, 2026 | clinicaltrials |
| NCT04742075 | Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer(DOVACC) | active not recruiting | Phase 2 | 188 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06240598 | A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy | active not recruiting | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03045965 | Hysterectomy and OPPortunistic SAlpingectomy(HOPPSA) | active not recruiting | N/A | 4,400 | Göteborg UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2026source: clinicaltrials